STOCK TITAN

Regeneron Pharmaceuticals - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Overview

Regeneron Pharmaceuticals (NASDAQ: REGN) is a renowned American biotechnology company dedicated to inventing, developing, and commercializing transformative medicines for serious diseases. With its headquarters in Westchester County, New York, and a history dating back to 1988, Regeneron has established itself as a trusted innovator in the biopharmaceutical industry by consistently translating cutting‐edge science into life‐changing therapies.

Core Business and Technological Excellence

At the heart of Regeneron’s operations lies a deep commitment to scientific rigor and technological innovation. The company leverages proprietary VelociSuite® technologies, which include the groundbreaking VelocImmune® platform, to generate fully human antibodies and next-generation bispecific antibodies. These advanced techniques enable Regeneron to identify novel targets and rapidly develop therapies across a wide spectrum of indications such as eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic conditions, hematologic disorders, and rare diseases.

Research, Development and Collaborative Approach

Regeneron’s robust R&D engine is fueled by decades of biology expertise and an integrated approach to drug discovery. The company’s research framework harnesses data-powered insights and genetic medicine platforms to drive its clinical research programs. This commitment is reflected in its diverse pipeline of product candidates and regulatory pathways that emphasize both innovation and patient safety. Through strategic partnerships and collaborations with other key industry players, Regeneron further strengthens its technological capacity while expanding its reach in translational medicine.

Market Position and Significance in the Biotechnology Sector

In the competitive landscape of biotech and pharmaceuticals, Regeneron distinguishes itself through its consistent ability to translate scientific discoveries into marketed products. Its portfolio comprises therapies addressing complex diseases by utilizing targeted approaches involving monoclonal antibodies and complementary biologic modalities. The company’s methodical process—from early identification of druggable targets to rigorous clinical testing and eventual commercialization—underscores its expertise, high scientific standards, and commitment to improving patient outcomes.

Operational Strategy and Business Model

Regeneron generates revenue primarily through its commercialization of innovative therapies and strategic collaborations, which amplify its research capabilities. By focusing on conditions with significant unmet medical need, Regeneron positions itself as a dynamic entity capable of addressing diverse therapeutic challenges. Its strategies incorporate efficient drug development processes, collaborative research initiatives, and maintaining robust clinical trial portfolios—all without relying on time-sensitive information or financial forecasts.

E-E-A-T Focus and Investor Considerations

The company’s work is grounded in long-standing scientific expertise and a commitment to ongoing research. By adhering to stringent safety and efficacy protocols and maintaining transparent regulatory communications, Regeneron exemplifies the principles of Expertise, Experience, Authoritativeness, and Trustworthiness (E-E-A-T). For investors and analysts, Regeneron’s approach to innovation, its state-of-the-art proprietary technologies, and its history of successfully translating advanced science into viable therapies present a well-articulated model of modern biotechnology excellence.

Conclusion

Overall, Regeneron Pharmaceuticals represents a compelling example of how rigorous research, technological innovation, and strategic partnerships converge to create transformative medicines. Its consistent emphasis on high-quality science and unbiased, evidence-based development processes not only boosts its market presence but also reinforces its reputation as a trusted biopharmaceutical partner in the global healthcare arena.

  • Decades of scientific expertise
  • Innovative proprietary platforms
  • Diverse therapeutic pipeline
  • Robust R&D and clinical programs
  • Strategic collaborations and transparency
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. receives Complete Response Letters from the FDA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma due to enrollment status issues in confirmatory trials. Despite this, no concerns were raised regarding clinical efficacy, safety, design, labeling, or manufacturing. Regeneron is actively enrolling patients in Phase 3 trials as part of the OLYMPIA program, aiming to revolutionize B-cell non-Hodgkin lymphoma treatment. The company is dedicated to collaborating with the FDA to expedite the availability of odronextamab for patients. Updates on enrollment and regulatory timelines are expected later this year, while EMA review continues for R/R DLBCL and R/R FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary
Achyuta Rajaram, 17, from Exeter, NH, wins the top award of $250,000 in the Regeneron Science Talent Search 2024. The competition, in its 83rd year, highlights young innovators in STEM fields. Other winners include Thomas Cong and Michelle Wei.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) receives FDA approval to extend the use of Praluent for children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). The approval allows Praluent to be used as an adjunct to diet and other LDL-C lowering therapies, providing a new treatment option for children with high LDL-C levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. announces positive results for EYLEA HD in treating wet age-related macular degeneration and diabetic macular edema. The Lancet published one-year data from PULSAR and PHOTON trials showing non-inferior vision gains with extended dosing regimens compared to standard care. EYLEA HD offers durable visual improvements, fluid control, and reduced treatment burden for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi's Dupixent granted Priority Review by FDA for potential COPD indication based on positive Phase 3 trial results, aiming to be the only biologic therapy for COPD and the first new treatment approach in over a decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) receives FDA Priority Review for linvoseltamab to treat relapsed/refractory multiple myeloma. The BLA is supported by Phase 1/2 trial data, with a target action date of August 22, 2024. Linvoseltamab aims to activate T cells for cancer-cell killing in MM patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi receive approval in Japan for Dupixent to treat chronic spontaneous urticaria, expanding its indications globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) will participate in several upcoming healthcare conferences, with webcasts available for investors and media. The sessions will be accessible from the company's website, with replays and transcripts archived for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported a 1% increase in fourth quarter 2023 revenues to $3.43 billion, with a 14% increase excluding Ronapreve. Full year 2023 revenues increased 8% to $13.12 billion, with a 12% increase excluding Ronapreve. The company's Dupixent global net sales increased significantly, with a 31% increase in the fourth quarter and a 33% increase for the full year. The GAAP diluted EPS was $10.19, and non-GAAP diluted EPS was $11.86 in the fourth quarter. The company's business update highlighted significant pipeline progress and upcoming milestones for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. announces the acceptance for review of the Marketing Authorization Application for linvoseltamab by the European Medicines Agency. The application is for the treatment of adult patients with relapsed/refractory multiple myeloma who have progressed after at least three prior therapies. The drug is an investigational bispecific antibody designed to facilitate T-cell activation and cancer-cell killing. The MAA is supported by data from a Phase 1/2 pivotal trial and a Biologics License Application was also submitted to the FDA. Multiple trials are planned or underway for linvoseltamab in different stages of multiple myeloma. MM is characterized by the proliferation of cancerous plasma cells and is not curable despite treatment advances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $617 as of April 1, 2025.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 67.6B.

What is the core focus of Regeneron Pharmaceuticals?

Regeneron is a biotechnology company that specializes in discovering, developing, and commercializing innovative medicines for serious diseases using advanced scientific and technological approaches.

Which technologies underpin Regeneron’s research efforts?

The company utilizes its proprietary VelociSuite® and VelocImmune® platforms, which are central to its ability to generate fully human antibodies and next-generation bispecific antibodies.

In which therapeutic areas does Regeneron operate?

Regeneron develops therapies across several areas including eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic and hematologic conditions, as well as rare diseases.

How does Regeneron generate its revenue?

Revenue is primarily generated through the commercialization of approved therapies and strategic collaborations that enhance its research and development capabilities.

What differentiates Regeneron in the competitive biotech landscape?

Its commitment to cutting-edge technology, robust R&D pipeline, and a collaborative approach enable Regeneron to consistently transform scientific discoveries into marketable and efficacious treatments.

How long has Regeneron been active in the biotechnology field?

Regeneron was founded in 1988 and has since built a reputable track record for translating innovative science into transformative therapies.

What are the key elements of Regeneron’s business model?

The model emphasizes rigorous research and development, leveraging proprietary technologies, strategic partnerships, and a focus on addressing unmet medical needs while maintaining high standards of safety and efficacy.

How does Regeneron maintain its E-E-A-T (Expertise, Experience, Authoritativeness, Trustworthiness) standards?

By consistently investing in advanced research, adhering to strict clinical protocols, engaging transparently with regulatory authorities, and fostering innovations through collaborations, Regeneron demonstrates deep expertise and builds trust in the medical and investment communities.
Regeneron Pharmaceuticals

Nasdaq:REGN

REGN Rankings

REGN Stock Data

67.56B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
TARRYTOWN